| Multiple Sclerosis |
1 |
1 |
| Monoclonal Antibody |
0 |
0.93 |
| Antineoplastic Drug |
0 |
0.55 |
| Myelin |
0 |
0.47 |
| Biologic Therapy |
0 |
0.45 |
| T-Lymphocyte |
0 |
0.25 |
| Disability |
0 |
0.23 |
| Lymphocytes |
0 |
0.23 |
| Multiple Sclerosis Relapse |
0 |
0.23 |
| Intravenous |
0 |
0.2 |
| Adverse Effects |
0 |
0.12 |
| Antigens |
0 |
0.12 |
| Cancer |
0 |
0.12 |
| Central Nervous System |
0 |
0.12 |
| Chemotherapy |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Immunosuppressive Therapy |
0 |
0.12 |
| Multiple Sclerosis Treatment |
0 |
0.12 |
| Muscle |
0 |
0.12 |
| Nerve |
0 |
0.12 |
| Pathogenesis |
0 |
0.12 |
| Weakness |
0 |
0.12 |
| Young Adult |
0 |
0.12 |
| Patient Safety |
0 |
0.05 |